Challenges in the Diagnosis of Neuroendocrine Tumors

Video

For High-Definition, Click

When referred to academic centers, many patients who have been diagnosed with a neuroendocrine tumor (NET) have received a broad assortment of tests and assays. In general, Rodney F. Pommier, MD notes, the first task when seeing these patients is to narrow down the information based on clinical parameters.

To determine diagnosis patterns, Pommier analyzed 150 patients with abdominal carcinoids. Out of these patients, only 3.5% of patients were referred 3 months following their initial presentation. The remaining 96.5% of patients received a diagnosis on average 6.5 years after presentation and even up to 20 years in some cases. In general, these patients receive 35 different initial diagnoses.

This delay, Pommier feels, may be related to the fact that community physicians are not initially thinking about carcinoids as a potential diagnosis. This is due to a combination of the natural characteristics of the disease and a lack of general awareness.

Related Videos
Adam S. Faye, MD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian